For example, E75, a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein, has been used as a vaccine to prevent disease recurrence in high-risk breast cancer patients [114]. Here, ERBB2 is linked to breast carcinoma.